All-trans retinoic-acid inhibits heterodimeric bone morphogenetic protein 2/7-stimulated osteoclastogenesis, and resorption activity

作者：Bi, Wenjuan; Liu, Yi; Guo, Jing; Lin, Zhen; Liu, Jinsong; Zhou, Miao; Wismeijer, Daniel; Pathak, Janak L.^*; Wu, Gang^*

来源：Cell and Bioscience, 2018, 8(1): 48.

DOI：10.1186/s13578-018-0246-y

• Heterodimeric bone morphogenetic protein 2/7
• All-trans retinoic acid
• Osteoclastogenesis
• Osteoclast activity
• Bone loss
• Bone regeneration

Background: Bone regenerative heterodimeric bone morphogenetic protein 2/7 (BMP2/7) enhances but all-trans retinoic acid (ATRA) inhibits osteoclastogenesis. However, the effect of ATRA on physiological and/or BMP2/7-induced osteoclastogenesis in still unclear. In this study, we aimed to test the effect of combined treatment of BMP2/7 and ATRA on osteoclastogenesis, and resorption activity.
Results: All-trans retinoic acid (1 mu M)+/- BMP2/7 (5 or 50 ng/ml) was added in murine pre-osteoclasts cell line RAW264.7 or mouse bone marrow derived macrophages (BMM) cultures. Osteoclast marker gene expression, osteoclastogenesis, and resorption activity were analyzed. BMP2/7 robustly enhanced osteoclast maker gene expression, osteoclastogenesis, and resorption activity. Interestingly, ATRA completely inhibited osteoclast formation in presence or absence of BMP2/7. Pan-antagonist of retinoic acid receptors (RARs) and antagonist of RARa, p or y failed to reverse the inhibitory effect of ATRA on osteoclastogenesis. ATRA strongly inhibited Rank and Nfatcl expression.
Conclusions: All-trans retinoic acid inhibits BMP2/7-induced osteoclastogenesis, and resorption activity possibly via RANKL-RANK pathway. Our findings from previous and current study suggest that combination of ATRA and BMP2/7 could be a novel approach to treat hyperactive osteoclast-induced bone loss such as in inflammation-induced severe osteoporosis and bone loss caused by cancer metastasis to bone.

• 出版日期2018-8-23
• 单位温州医科大学; 中国科学技术大学; 暨南大学; 广州医科大学